We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Stuart
Ralston
+44 (0)1316518741
stuart.ralston@ed.ac.uk
Ms
Kathryn
Berg
+44 (0)1316518755
kathryn.berg@ed.ac.uk
Ms
Kathryn
Berg
+44 (0)1316518755
kathryn.berg@ed.ac.uk
Paget's disease of bone
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Epidemiological studies have shown that environmental factors influence the occurrence and severity of Paget’s disease of bone (PDB), but the identity of these factors is unclear. There is previous evidence that dietary calcium and vitamin D deficiency might predispose to PDB. The study will investigate the role of dietary calcium and vitamin D and of the microbiome as environmental factors which may modify the disease activity in PDB. The aim of this study will be to explore the effects of dietary calcium and vitamin D supplements and probiotic supplements on biochemical markers of metabolic activity in patients with mild PDB who are not considered to require treatment with bisphosphonate therapy and to study effects on pain and quality of life.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Unable or unwilling to give informed consent2. Bisphosphonate therapy thought to be indicated for the treatment of Paget's disease of the bone on clinical grounds3. Currently being treated with bisphosphonates, denosumab or calcitonin for any reason4. Currently being treated with combined calcium and vitamin D supplements5. Treatment with oral or intravenous bisphosphonates during the previous 24 months6. Treatment with denosumab during the past 12 months7. Treatment with calcitonin during the previous 3 months.8. Treatment with combined calcium and vitamin D supplements during the past 4 weeks9. Receiving probiotics during the previous 3 months
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Ms
Kathryn
Berg
+44 (0)1316518755
kathryn.berg@ed.ac.uk
Prof
Stuart
Ralston
+44 (0)1316518741
stuart.ralston@ed.ac.uk
Ms
Kathryn
Berg
+44 (0)1316518755
kathryn.berg@ed.ac.uk
The study is sponsored by Accord (United Kingdom) and funded by H2020 European Research Council.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
